Arecor Therapeutics
AREC · AIM · Health Care · mcap £28m · 72.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 08 Oct 26 | Results | Half Year Results Investor Presentation
Cambridge, UK, 8 October 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, |
+0.0% |
| 08 Oct 26 | Holding | Holding(s) in Company | |
| 07 Oct 26 | Fundraise | Result of Retail Offer
Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabo |
+0.0% |
| 30 Sep 26 | Fundraise | Retail Offer to raise up to £130,000
Retail Offer to raise up to £0.13 million |
−18.1% |
| 30 Sep 26 | Results | Results of Placing
A separate announcement will be made shortly by the Company in relation to the Retail Offer and shall include its terms and timetable. |
−18.1% |
| 30 Sep 26 | Close of Accelerated Bookbuild to New Orders
Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabo |
−18.1% | |
| 30 Sep 26 | Fundraise | Proposed Fundraising to raise up to £5.13 million
Proposed Fundraising to raise up to £5.13 million |
−18.1% |
| 30 Sep 26 | Results | Half-year Results
Interim results for the six months to 30 June 2026 |
−18.1% |
| 13 Aug 26 | AT278 data published in peer-reviewed journal
· Findings support AT278's potential as first ultra-rapid U500 option for insulin resistance in people with type 2 diabetes requiring high-dose therapy, regardless of BMI |
+0.0% | |
| 10 Aug 26 | Holding | Holding(s) in Company | |
| 28 May 26 | Routine | Result of AGM | |
| 21 May 26 | Director dealing | Grant of options and PDMR dealing | |
| 18 May 26 | Upcoming conference attendance
Cambridge, UK, 18 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, ob |
+0.0% | |
| 28 Apr 26 | Routine | Posting of Annual Report and Notice of AGMm | |
| 13 Apr 26 | Results | Final Results
Cambridge, UK, 13 April 2026: Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, |
+2.3% |
| 30 Mar 26 | Notice of FY25 Results
Cambridge, UK, 30 March 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, |
+0.0% | |
| 26 Mar 26 | Ligand Pharmaceuticals Milestone Payment
$0.5 Million Commercial Milestone Payment From Ligand Pharmaceuticals |
+3.0% | |
| 09 Mar 26 | Arecor to present at Oppenheimer conference
Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference |
+0.0% | |
| 09 Feb 26 | 2025 Business Update
Cambridge, UK, 9 February 2026: Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on drug development and enhanced delivery in diabetes and other cardiometabolic diseases, provides a business updat |
+0.0% | |
| 06 Jan 26 | Fireside Panel Discussion on Diabetes sector
Arecor and Sequel Med Tech virtual fireside panel discussion |
+4.1% | |
| 09 Dec 25 | Arecor and Sequel Med Tech to host fireside panel
Arecor and Sequel Med Tech to host virtual fireside panel discussion |
+1.9% | |
| 17 Nov 25 | Holding | Holding(s) in Company | |
| 11 Nov 25 | Holding | Holding(s) in Company | |
| 04 Nov 25 | Enhanced IP Coverage: AT278 & Oral Peptide Program
Arecor Enhances IP Coverage for AT278 and Oral Delivery Technology |
+1.4% |
Company filings. Not investment advice.